Truist on Madrigal Pharmaceuticals (MDGL): 'In-Licensed Asset Potentially Strengthens Pipeline'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $640.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
